Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-04-03
2007-04-03
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S138100, C424S143100, C424S146100
Reexamination Certificate
active
10143553
ABSTRACT:
Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration.
REFERENCES:
patent: 5120642 (1992-06-01), Schlossman et al.
patent: 6218372 (2001-04-01), Nabel et al.
patent: 6573096 (2003-06-01), Chen
patent: WO 01/74299 (2001-10-01), None
patent: WO 02/04610 (2002-01-01), None
patent: WO 02/31134 (2002-04-01), None
Voet et al., (1990, Biochemistry, John Wiley & Sons, pp. 964, 965, 1074, and 1075).
Aldinucci et al., (2000, British Journal of Haematology, vol. 110, pp. 188-196).
Asada et al., “Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma,”Histopathol., 23:265-270, 1993.
Bauvois et al., “Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia,”Br. J. Cancer, 79:1042-1048, 1999.
Carbone et al., “CD26/dipeptidyl peptidase IV expression in human lymphomas is restricted to DC30-positive anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas,”Human Pathol., 25:1360-1365, 1994.
Carbone et al., “The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias,”Blood, 86(12):4617-4616, 1995.
Dang et al., “1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation,”J. Immunol., 147:2825-2832, 1991.
Dang et al., “Cell surface modulation of CD26 by aniti-1F7 monoclonal antibody,”J. Immunol., 145:3963-3971, 1990.
Dang et al., “Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways,”J. Immunol., 144:4092-4100, 1990.
Dang et al., “FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation,”Cell Immunol., 125:42-57, 1990.
Dang et al., “Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family,”J. Exp. Med., 172:649-652, 1990.
Datto et al., “Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism,”Proc. Natl. Acad. Sci. USA, 92:5545-5549, 1995.
De Meester, et al., “Antibody-binding profile of purified and cell-bound CD26—designation of BT5/9 and TA5.9 to the CD26 cluster,”Immunobiology, 188:145-158, 1993.
Dong et al., “Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response,”J. Immunology, 156:1349-1355, 1996.
Dong et al., “Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function,”Mol. Immunol., 35:13-21, 1998.
El-Deiry et al., “WAF1, a potential mediator of p53 tumor suppression,”Cell, 75:817-825, 1993.
El-Deiry et al., “WAF1/CIP1 is induced in p53-mediated G1arrest and apoptosis,”Cancer Res., 54:1169-1174, 1994.
Fleischer et al., “Molecular associations required for signaling via dipeptidyl peptidase IV (CD26),”Adv. Exp. Med. Biol., 421:117-125, 1997.
Fleischer, “A novel pathway of human T cell activation via a 103 kD T cell activation antigen,”J. Immunol., 138:1346-1350, 1987.
Fox et al., “Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody,”J. Immunol., 133:1250-1256, 1984.
Hegen et al., “Cross-linking of CD26 by antibody induces tyorsine phosphorylation and activation of mitogen-activated protein kinase,”Immunology, 90:257-264, 1997.
Hühn et al., “Molecular analysis of CD26-mediated signal transduction in T cells,”Immunology Letters, 72:127-132, 2000.
Hühn et al., “The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV (CD26) molecule,”Cellular Immunology, 192:33-40, 1999.
Kähne et al., “Early phosphorylation events induced by DPIV/CD26-specific inhibitors,”Cell. Immunol., 189:60-66, 1998.
Kubota et al., “Involvement of dipeptidyl peptidase IV in an in vivo immune response,”Clin. Exp. Immunol., 89:192-197, 1992.
Mattern et al., “Antin-CD26 monoclonal antibodies can reversibly arrest human T lymphocytes in the late G1phase of the cell cycle,”Immunobiol., 188:36-50, 1993.
Morimoto and Schlossman, “The structure and function of CD26 in the T-cell immune response,”Immunol. Rev., 161:55-70, 1998.
Morimoto et al., “1F7, a novel cell surface molecule, involved in helper function of CD4 cells,”J. Immunol., 143:3430-3439, 1989.
Morimotoet al., “The isolation and characterization of the human helper inducer T cell subset,”J Immunol., 134:3762-3769, 1985.
Morrison et al., “A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase,”J. Exp. Med., 177; 1135-1143, 1993.
Tanaka et al., “CD26 (Dipeptidyl peptidea IV/DPP IV) as a novel molecular marker for differntiated tyroid carcinoma,”Int. J. Cancer, 64:326-331, 1995.
Tanaka et al., “Cloning and functional expression of the T cell activation antigen CD26,”Journal of Immunology, 149:481-486, 1992.
Tanaka et al., “The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity,”Proc. Natl. Acad. Sci. USA, 90:4586-4590, 1993.
Torimoto et al., “Biochemical characterization of CD26 (dipeptidyl peptidae IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies,”Mol. Immunol., 29:183-192, 1992.
Torimoto et al., “Coassociation of CD26 (Dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes,”J. Immunol., 147:2514-2517, 1991.
von Bonin et al., “Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway,”Immunol Rev., 161:43-53, 1998.
von Bonin et al., “The T-cell receptor associated ξ-chain is required but not sufficient for CD26 (dipeptidylpeptidase IV) mediated signaling,”Immunology Letters, 55:179-182, 1997.
Waga et al., “The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA,”Nature, 369:574-578, 1994.
Wesley et al., “A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells,”J. Exp. Med., 190:311-322, 1999.
Yang and Kornbluth, “All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners,”Trends Cell Biol., 9:207-210, 1999.
Ho et al., “In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma karpas 299,”Clinical Cancer Res., 7:2031-2040, 2001.
Dang Nam Hoang
Morimoto Chikao
Schlossman Stuart
Board of Regents , The University of Texas System
Dana-Farber Cancer Institute
Fulbright & Jaworski L.L.P.
Yu Misook
LandOfFree
Anti-CD26 monoclonal antibodies as therapy for diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD26 monoclonal antibodies as therapy for diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD26 monoclonal antibodies as therapy for diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3790760